Sigyn Therapeutics, Inc. (SIGY)
USD 4.15
(3.75%)
USD 4.15
(3.75%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 321.8 Thousand USD | -3.33% |
| 2022 | 332.87 Thousand USD | -53.13% |
| 2021 | 710.25 Thousand USD | 2.33% |
| 2020 | 694.08 Thousand USD | 8.09% |
| 2019 | 642.14 Thousand USD | -25.51% |
| 2018 | 862.04 Thousand USD | -58.38% |
| 2017 | 2.07 Million USD | -11.57% |
| 2016 | 2.34 Million USD | 64.13% |
| 2015 | 1.42 Million USD | 153.79% |
| 2014 | 562.26 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 320.16 Thousand USD | -0.97% |
| 2024 Q1 | 323.29 Thousand USD | 0.46% |
| 2023 Q2 | 361.81 Thousand USD | -45.22% |
| 2023 Q4 | 321.8 Thousand USD | -16.89% |
| 2023 FY | 321.8 Thousand USD | -3.33% |
| 2023 Q3 | 387.22 Thousand USD | 7.02% |
| 2023 Q1 | 660.44 Thousand USD | 98.4% |
| 2022 Q3 | 362.27 Thousand USD | -8.5% |
| 2022 Q4 | 332.87 Thousand USD | -8.11% |
| 2022 Q2 | 395.9 Thousand USD | -11.51% |
| 2022 Q1 | 447.41 Thousand USD | -37.01% |
| 2022 FY | 332.87 Thousand USD | -53.13% |
| 2021 Q2 | 1.99 Million USD | 227.21% |
| 2021 Q4 | 710.25 Thousand USD | -50.7% |
| 2021 FY | 710.25 Thousand USD | 2.33% |
| 2021 Q1 | 608.96 Thousand USD | -12.26% |
| 2021 Q3 | 1.44 Million USD | -27.69% |
| 2020 Q4 | 694.08 Thousand USD | 13.75% |
| 2020 Q2 | 622.69 Thousand USD | -1.72% |
| 2020 Q1 | 633.57 Thousand USD | -1.33% |
| 2020 FY | 694.08 Thousand USD | 8.09% |
| 2020 Q3 | 610.18 Thousand USD | -2.01% |
| 2019 Q4 | 642.14 Thousand USD | -15.86% |
| 2019 FY | 642.14 Thousand USD | -25.51% |
| 2019 Q3 | 763.15 Thousand USD | -4.47% |
| 2019 Q2 | 798.83 Thousand USD | -3.29% |
| 2019 Q1 | 826 Thousand USD | -4.18% |
| 2018 Q4 | 862.04 Thousand USD | -53.83% |
| 2018 Q3 | 1.86 Million USD | -3.41% |
| 2018 Q2 | 1.93 Million USD | -5.49% |
| 2018 Q1 | 2.04 Million USD | -1.25% |
| 2018 FY | 862.04 Thousand USD | -58.38% |
| 2017 Q4 | 2.07 Million USD | -2.69% |
| 2017 Q1 | 2.2 Million USD | -5.88% |
| 2017 FY | 2.07 Million USD | -11.57% |
| 2017 Q2 | 2.22 Million USD | 1.03% |
| 2017 Q3 | 2.12 Million USD | -4.44% |
| 2016 Q2 | 1.15 Million USD | -10.53% |
| 2016 Q3 | 1.05 Million USD | -8.6% |
| 2016 Q1 | 1.29 Million USD | -9.3% |
| 2016 FY | 2.34 Million USD | 64.13% |
| 2016 Q4 | 2.34 Million USD | 121.3% |
| 2015 Q3 | 880.87 Thousand USD | 0.0% |
| 2015 Q4 | 1.42 Million USD | 62.0% |
| 2015 FY | 1.42 Million USD | 153.79% |
| 2014 FY | 562.26 Thousand USD | 0.0% |
| 2014 Q4 | 562.26 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -13830.996% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 83.566% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 96.951% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 41.714% |
| Rebus Holdings, Inc. | 5000.00 USD | -6336.12% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.753% |
| Qrons Inc. | 420.00 USD | -76520.476% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 58.242% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 98.848% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 33.035% |
| Skye Bioscience, Inc. | 11.94 Million USD | 97.305% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.172% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 95.543% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -321.466% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.7% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 77.528% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -344.698% |
| Mesoblast Limited | 667.9 Million USD | 99.952% |
| Marizyme, Inc. | 22.01 Million USD | 98.538% |
| Genus plc | 1.02 Billion USD | 99.969% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 76.309% |
| Pharming Group N.V. | 462.85 Million USD | 99.93% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 90.287% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 35.515% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 48.675% |
| ContraFect Corporation | 20.67 Million USD | 98.444% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 17.563% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 15.797% |
| IMV Inc. | 31.33 Million USD | 98.973% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 92.238% |
| MultiCell Technologies, Inc. | 126.22 USD | -254856.425% |
| ONE Bio Corp. | 70.08 Million USD | 99.541% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 65.754% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.75% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 25.459% |
| Q BioMed Inc. | 3.51 Million USD | 90.846% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.085% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -23.167% |
| Biomind Labs Inc. | 73.81 Thousand USD | -335.939% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.928% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 77.789% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 98.928% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 88.282% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 53.191% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 87.638% |
| GB Sciences, Inc. | 103.44 Thousand USD | -211.098% |
| Alpha Cognition Inc. | 2.45 Million USD | 86.877% |
| HST Global, Inc. | 1526.00 USD | -20988.204% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 67.427% |
| Halberd Corporation | 10.13 Thousand USD | -3076.449% |
| Enzolytics Inc. | 361.7 Million USD | 99.911% |
| Agentix Corp. | 261.39 Thousand USD | -23.112% |
| Resverlogix Corp. | 8.11 Million USD | 96.034% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 82.863% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.993% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.325% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 49.691% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1312.607% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 96.404% |
| AVAX Technologies, Inc. | 7.37 Million USD | 95.638% |
| Zenith Capital Corp. | 7410.00 USD | -4242.861% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.99% |
| Ember Therapeutics, Inc. | 184.00 USD | -174794.565% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -23.126% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 65.321% |
| Kadimastem Ltd | 2.3 Million USD | 86.033% |
| Helix BioMedix, Inc. | 3.02 Million USD | 89.362% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.389% |
| BioStem Technologies, Inc. | 14.56 Million USD | 97.79% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -463.642% |
| LadRx Corporation | 2.3 Million USD | 86.056% |
| Cell Source, Inc. | 195.17 Thousand USD | -64.884% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 8.996% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 8.996% |
| NovAccess Global Inc. | 62.24 Thousand USD | -416.974% |
| Affymax, Inc. | 7.44 Million USD | 95.676% |
| Itoco Inc. | 1.4 Million USD | 77.015% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -236.417% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -203.591% |
| Mobile Lads Corp. | 52.00 USD | -618757.692% |
| CytoDyn Inc. | 11.13 Million USD | 97.11% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -125.083% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -1699.81% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 16.516% |
| SYBLEU INC | 330.46 Thousand USD | 2.621% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 21.4% |
| International Stem Cell Corporation | 5.39 Million USD | 94.03% |
| Bioxytran, Inc. | 137.63 Thousand USD | -133.806% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 97.855% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 98.059% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -307.349% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 62.783% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 95.719% |
| Neutra Corp. | 2851.00 USD | -11187.478% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.007% |
| PureTech Health plc | 693.97 Million USD | 99.954% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 96.013% |
| IXICO plc | 15.84 Million USD | 97.969% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 96.114% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.689% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Cellectis S.A. | 333.99 Million USD | 99.904% |